Our study reveals that the effect of host STAT1 deficiency on tumor development can be reversed upon IL-17-blockade treatment, which correlates with a decreased accumulation of CD11b+ Ly6ClowLy6G+ cells and neutrophils and a remarkable reduction in tumor growth. The gene discussed is IL17A; the disease is neoplasm.